Acknowledging the neuroprotective effects of erythropoietin (EPO) on the survival and regeneration of neurons in AD [18,19] and the previously demonstrated reduction in EPO/EPO receptor expression in the brain of APP/PS1 mice [20], we assessed its cerebral level in vehicle vs. losartan treated APP/PS1 mice. This evidence concerns the gene EPO and Alzheimer disease.